$20.4 M

SLS Mkt cap, 09-Jul-2020
Sellas Life Sciences Net income (Q1, 2020)-4.1 M
Sellas Life Sciences Cash, 31-Mar-20206.7 M
Sellas Life Sciences EV13.9 M

Sellas Life Sciences Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.5m9.3m

Cost of goods sold

520.0k1.4m

Gross profit

2.0m7.9m

Gross profit Margin, %

79%85%

R&D expense

11.5m14.6m21.1m28.4m23.6m19.9m6.1m8.8m7.3m

General and administrative expense

9.2m6.6m15.1m12.8m9.9m

Operating expense total

20.8m21.2m35.8m60.1m23.6m19.9m21.2m23.6m17.9m

EBIT

(33.3m)(33.8m)(52.2m)(34.2m)(31.9m)(23.0m)

EBIT margin, %

(1361%)(560%)

Interest expense

6.0k1.0k547.0k800.0k266.0k118.0k

Pre tax profit

(11.5m)(34.4m)(75.6m)(36.6m)(38.6m)(10.9m)(23.5m)(29.0m)(19.4m)

Income tax expense

(1.1m)1.1m365.0k243.0k253.0k(1.4m)(81.0k)

Net Income

(11.5m)(35.0m)(76.7m)(36.6m)(63.9m)(23.5m)(23.8m)(27.7m)(19.3m)

Sellas Life Sciences Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

17.9m15.7m8.7m19.2m15.4m17.5m20.9m51.4m52.4m39.2m24.6m52.9m45.3m34.7m19.6m24.5m27.6m18.1m12.9m3.5m1.3m10.0m2.6m12.8m9.1m6.7m

Accounts Receivable

1.5m1.5m2.2m1.4m1.1m1.8m6.6m

Prepaid Expenses

259.0k494.0k290.0k760.0k801.0k210.0k389.0k485.0k1.3m1.7m1.8m2.6m2.4m1.1m1.2m1.0m449.0k434.0k520.0k986.0k931.0k651.0k726.0k776.0k977.0k1.9m

Inventories

352.0k425.0k358.0k433.0k450.0k637.0k1.4m

Current Assets

18.2m16.2m9.1m20.1m16.3m27.5m27.5m56.8m55.8m43.7m28.5m57.3m51.1m37.9m45.3m44.5m42.0m32.3m26.6m13.1m10.9m17.8m3.4m13.6m10.2m8.8m

PP&E

436.0k430.0k351.0k34.0k31.0k27.0k467.0k545.0k653.0k623.0k589.0k528.0k532.0k299.0k259.0k226.0k173.0k148.0k123.0k

Goodwill

845.0k845.0k5.9m5.9m5.9m5.9m5.9m5.9m5.9m5.9m5.9m6.1m6.1m5.9m5.9m5.9m5.9m5.9m5.4m1.9m1.9m1.9m1.9m1.9m1.9m1.9m

Total Assets

32.4m30.3m28.2m39.0m35.2m61.5m62.0m91.3m92.3m80.3m79.5m108.6m102.0m66.4m73.8m72.8m70.3m60.6m49.6m33.5m32.0m38.5m14.9m25.0m21.5m17.0m

Accounts Payable

1.1m1.5m2.6m1.7m2.2m2.1m2.1m1.9m1.6m2.0m3.4m3.3m2.3m1.0m1.3m894.0k1.2m385.0k211.0k11.5m12.1m7.2m4.6m3.8m3.8m2.6m

Short-term debt

59.0k65.0k24.0k12.0k6.0k6.0k301.0k1.2m3.1m4.1m4.2m4.0m4.1m3.7m23.2m23.7m12.6m12.2m8.5m7.8m76.0k359.0k362.0k306.0k123.0k

Current Liabilities

16.8m21.5m27.4m9.3m10.1m26.4m25.8m36.5m26.8m33.4m31.6m34.0m38.1m42.2m47.2m42.5m36.3m34.5m28.0m25.7m24.9m12.0m5.8m5.4m5.6m3.6m

Long-term debt

10.0k14.0k36.0k45.0k51.0k51.0k9.4m8.6m6.9m6.0m5.1m3.5m2.5m1.2m583.0k418.0k306.0k123.0k

Total Debt

69.0k79.0k60.0k57.0k57.0k57.0k9.7m9.8m10.0m10.1m9.3m7.5m6.6m3.7m23.2m23.7m12.6m12.2m9.7m7.8m76.0k942.0k780.0k612.0k246.0k

Total Liabilities

22.5m25.6m38.8m19.8m21.0m38.1m46.8m56.6m45.8m52.0m48.6m49.5m52.6m54.0m53.5m48.9m43.1m41.4m35.0m34.8m34.5m20.0m12.0m10.7m10.8m9.0m

Common Stock

4.0k4.0k5.0k7.0k7.0k8.0k8.0k10.0k11.0k11.0k11.0k15.0k15.0k18.0k18.0k20.0k4.0k4.0k4.0k1.0k1.0k2.0k2.0k10.0k5.0k7.0k

Preferred Stock

Additional Paid-in Capital

74.7m77.4m85.3m115.1m116.5m132.7m136.6m167.1m231.8m233.5m242.2m288.9m294.9m312.1m314.6m325.2m345.7m346.0m347.6m60.9m65.8m87.0m89.3m103.9m104.4m113.3m

Retained Earnings

(61.0m)(323.1m)(329.1m)(62.2m)(68.2m)(68.5m)(86.4m)(89.5m)(93.7m)(105.3m)

Total Equity

9.9m4.7m(10.6m)19.1m14.2m23.3m15.2m34.6m46.5m28.3m30.9m59.1m49.4m12.4m20.3m23.9m27.2m19.1m14.6m(1.3m)(2.5m)18.5m3.0m14.3m10.6m8.1m

Debt to Equity Ratio

0 x0.3 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

3.3 x6.4 x-2.7 x2 x2.5 x2.6 x4.1 x2.6 x2 x2.8 x2.6 x1.8 x2.1 x5.3 x3.6 x3 x2.6 x3.2 x3.4 x-25.4 x-12.9 x2.1 x5.1 x1.7 x2 x2.1 x

Sellas Life Sciences Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.5m)(35.0m)(76.7m)(36.6m)(23.8m)(27.7m)(19.3m)

Depreciation and Amortization

163.0k49.0k452.0k889.0k355.0k142.0k

Accounts Receivable

(3.7m)1.6m

Inventories

(386.0k)(269.0k)

Accounts Payable

500.0k641.0k684.0k(389.0k)(289.0k)(757.0k)8.4m(7.9m)12.0k

Cash From Operating Activities

(14.7m)(21.0m)(28.9m)(42.9m)(48.2m)(44.9m)(11.0m)(30.4m)(17.6m)

Purchases of PP&E

(53.0k)(705.0k)(57.0k)(153.0k)(6.0k)

Cash From Investing Activities

14.0k(87.0k)(12.0m)(5.5m)10.4m(1.1m)1.8m

Long-term Borrowings

(84.0k)(10.0k)(25.0k)(5.6m)(473.0k)(7.6m)

Dividends Paid

(487.0k)

Cash From Financing Activities

19.2m42.4m55.9m24.3m43.8m34.3m5.5m23.1m19.6m

Net Change in Cash

4.5m21.4m15.0m(24.1m)6.1m(11.6m)(3.6m)(7.3m)1.9m

Interest Paid

6.0k1.0k547.0k800.0k541.0k636.0k321.0k

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(5.2m)(13.1m)(24.8m)(25.0m)(31.2m)(9.3m)(18.9m)(28.2m)(2.5m)(22.5m)(28.6m)(10.5m)(26.2m)(13.1m)(4.8m)(9.2m)(2.3m)(9.4m)(15.6m)(8.0m)(14.1m)(14.3m)(4.5m)(7.7m)(11.9m)(4.1m)

Depreciation and Amortization

84.0k126.0k42.0k44.0k47.0k2.0k41.0k168.0k232.0k461.0k665.0k264.0k816.0k73.0k777.0k1.4m26.0k51.0k76.0k

Accounts Receivable

(1.5m)2.2m1.5m2.2m779.0k21.0k(6.6m)

Inventories

(352.0k)(425.0k)28.0k(47.0k)(64.0k)18.0k(771.0k)

Accounts Payable

(590.0k)(193.0k)426.0k371.0k875.0k147.0k116.0k(86.0k)(1.1m)(624.0k)700.0k1.0m47.0k(578.0k)(324.0k)(703.0k)323.0k(455.0k)(629.0k)(240.0k)408.0k(4.5m)883.0k(263.0k)(227.0k)(1.3m)

Cash From Operating Activities

(7.1m)(10.5m)(4.9m)(11.6m)(15.8m)(5.3m)(12.5m)(20.4m)(8.0m)(21.0m)(32.1m)(11.6m)(23.4m)(13.2m)(24.7m)(36.9m)(10.4m)(20.0m)(26.2m)(5.4m)(11.7m)(25.9m)(5.0m)(9.6m)(13.5m)(6.8m)

Purchases of PP&E

(53.0k)(53.0k)(450.0k)(554.0k)(22.0k)(29.0k)(48.0k)(18.0k)(69.0k)(6.0k)(6.0k)(6.0k)

Cash From Investing Activities

115.0k115.0k(87.0k)(87.0k)(10.1m)(10.0m)(9.2m)(2.0m)(2.3m)(5.4m)(518.0k)(569.0k)(1.1m)(1.1m)(1.1m)(18.0k)(25.0k)

Long-term Borrowings

(47.0k)(73.0k)(7.0k)(10.0k)(10.0k)(17.0k)(21.0k)(3.0k)(7.0k)(917.0k)(947.0k)(1.9m)(1.0m)(4.8m)(4.8m)(110.0k)(589.0k)(589.0k)(7.5m)

Dividends Paid

(111.0k)(487.0k)

Cash From Financing Activities

18.0m19.2m2.2m19.5m19.9m92.0k10.5m48.3m14.7m14.7m14.4m41.3m45.6m19.3m15.6m32.8m20.0m20.0m21.1m4.7m8.9m23.2m2.2m17.1m17.3m6.3m

Net Change in Cash

11.0m8.8m(2.7m)7.8m4.0m(15.3m)(11.9m)18.6m4.6m(8.6m)(23.1m)29.2m21.6m5.0m(10.1m)(5.2m)9.6m(10.0k)(5.2m)(664.0k)(2.8m)(2.7m)(2.8m)7.4m3.8m(531.0k)

Interest Paid

4.0k1.0k36.0k(53.0k)632.0k166.0k312.0k112.0k606.0k636.0k102.0k102.0k110.0k182.0k321.0k

Sellas Life Sciences Ratios

USDQ2, 2011

Financial Leverage

3.3 x